AP, December 18, 2022: Patients with ALS (also called Lou Gehrig’s disease) celebrated when FDA approved Relyvrio in 2022. But it costs $158k despite combining two old ingredients, the benefits are unclear, and the effective ingredient may be the one sold by Amazon for $1/day. Important research is underway to find out if the ingredient available on Amazon is equally or more effective, says Dr. Diana Zuckerman of National Center for Health Research.
Read More »Author: Caroline Bradford
Fitness Tracking Apps and Eating Disorders
Belinda Gorsuch, National Center for Health Research December 15, 2022 It seems there is an app for everything. About 69% of adults track health indicators, such as steps, calories, and hydration [1]. But, has fitness tracking technology gone too far? Some believe our phones can help us improve our diet and exercise routines. Others claim […]
Read More »NCHR Letter to Senate HELP and House Energy & Commerce Committees Regarding the VALID Act
December 14, 2022: We strongly support the inclusion of the VALID Act in the year-end omnibus spending package. This important bill will provide the FDA with the authority and resources necessary to ensure that the highest-risk diagnostic tests are valid and reliable.
Read More »NCHR encourages WSPI to do more to prevent long-term impact of diabetes in pregnancy
December 8, 2022: The National Center for Health Research (NCHR) agrees with the Women’s Preventive Services Initiative (WPSI) 2022 recommendations for diabetes screening after pregnancy. WPSI encourages continued diligence during the postpartum period in patients who were diagnosed with diabetes mellitus during pregnancy. That’s important because gestational diabetes increases a patient’s chances of developing type 2 diabetes.
Read More »Lasik Patients Should Be Warned of Complications, F.D.A. Draft Says
New York Times, December 7, 2022: FDA says many Lasik surgery patients develop double vision, dry eyes, difficulty driving at night and some have persistent eye pain. Diana Zuckerman says these FDA warnings should be required.
Read More »